J. Joseph Kim

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) said Thursday it’s observed a 100-percent antibody response in a phase I study for a Zika virus vaccine and a 92 percent antibody response in a phase I study for a MERS vaccine. The findings were presented at a Coalition for Epidemic Preparedness...

Inovio Pharmaceuticals Inc (NASDAQ: INO) plans to complete its testing of a Zika vaccine in mice and monkeys by the third quarter of this year before moving to a Phase 1 study in Q4, a company spokesperson told Benzinga. The company said it plans to produce between 5,000 and 10,000 doses by Q3...